Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OriV508
- Development stage
- Phase 1
- Lead developer
- OriCell Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
OriV508 is a non-replicative, self-inactivating lentiviral vector-based therapy that carries a dual-target chimeric antigen receptor (CAR) directed against both B-cell maturation antigen (BCMA) and CD19. It is designed for use as CAR-T cell therapy in hematological malignancies, enabling patient T cells to recognize and eliminate cells expressing either BCMA or CD19 antigens.[1] The therapeutic mechanism combines targeting of BCMA (predominantly expressed in multiple myeloma and some other B-cell malignancies) and CD19 (expressed in various B-cell lineage cancers). OriV508 is currently under investigation in clinical trials specifically for relapsed or refractory hematologic malignancies.[1][2][4] The developer is presumed to be OriCell Therapeutics, based on standard clinical trial coding conventions for "OriV" codenamed assets, though this should be verified if further company-specific data become available.
- Brand names
- OriV508OriV-508OriV 508
- Other names
- OriV508 injectionOriV-508 injectionOriV 508 injection
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on OriV508.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OriV508.